SynVaccine

Company Overview

Snapshot

Founded in July 2013 by Tamir Tuller and Tuval Ben Yehezkel, SynVaccine operates with 1–10 employees. The company has raised $1.76M across two funding rounds from six investors. In November 2017, SynVaccine secured funding from A2Z Venture Partners and Pix Vine Capital.

Business overview

SynVaccine is a Health Tech & Life Sciences company specializing in the design and fabrication of designer viruses for biotechnology. The company leverages a multidisciplinary approach, integrating synthetic biology, virology, bioinformatics, engineering, and robotics to create novel viruses for vaccine development. Its technology focuses on designing and fabricating viral genomes with an emphasis on safety, aiming to overcome the limitations of naturally occurring viruses or those developed through traditional methods. SynVaccine operates within the Pharmaceuticals and Biotechnology sectors, serving the life sciences and healthcare industries with its CAD/CAM platform for viral-based products.

Company Intelligence Q&A

What is SynVaccine's core technology?

SynVaccine has developed a CAD/CAM platform for designing and fabricating designer viruses for biotechnology, utilizing synthetic biology, virology, bioinformatics, engineering, and robotics.

When was SynVaccine founded and by whom?

SynVaccine was founded in July 2013 by Tamir Tuller and Tuval Ben Yehezkel.

What was a significant funding event for SynVaccine?

In November 2017, SynVaccine raised funding from investors including A2Z Venture Partners.

What is the total capital raised by SynVaccine?

SynVaccine has raised a total of $1.76M across two funding rounds.